Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 201–300 of 1,004
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 174
Zhang, Z., Teruya, K., Yoshida, T., Eto, H., & Shirahata, S. (2013) · Marine Drugs · doi:10.3390/md11010081 · Cited by 150
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Chen, M.-F., Chen, P.-T., Lu, M. S., Lin, P. Y., Chen, W.-C., & Lee, K.-D. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-26 · Cited by 150
Kasherman, Y., Sturup, S., & Gibson, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900138u · Cited by 150
Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity
Martinho, N., Santos, T. C. B., Florindo, H. F., & Silva, L. C. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01898 · Cited by 161
“Resistance to Cisplatin Induced by Changes on Membrane Biophysical Properties and Sphingolipid Metabolism A large fraction of human malignancies rapidly becomes (or intrinsically is) insensitive to the cytotoxic effects of cisplatin (Siddik, 2003; Galluzzi et al., 2014).”
BackgroundInfluentialThe role of DNA repair pathways in cisplatin resistant lung cancer
O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 161
Stable Anticancer Gold(III)–Porphyrin Complexes: Effects of Porphyrin Structure
Sun, R. W., Li, C. K.-L., Ma, D., Yan, J. J., Lok, C., Leung, C., Zhu, N., & Che, C. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200902741 · Cited by 149
Watson, J. L., Greenshields, A. L., Hill, R., Hilchie, A. L., Lee, P. W. K., Giacomantonio, C. A., & Hoskin, D. W. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20571 · Cited by 152
A highly annotated database of genes associated with platinum resistance in cancer
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021) · Oncogene · doi:10.1038/s41388-021-02055-2 · Cited by 161
Jiang, M., Wei, Q., Pabla, N., Dong, G., Wang, C., Yang, T., Smith, S. B., & Dong, Z. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.010 · Cited by 149
Oh, G.-S., Kim, H.-J., Choi, J.-H., Shen, A., Choe, S.-K., Karna, A., Lee, S. H., Jo, H.-J., Yang, S.-H., Kwak, T. H., et al. (2014) · Kidney International · doi:10.1038/ki.2013.330 · Cited by 147
Anticancer activity of palladium-based complexes against triple-negative breast cancer
Vojtek, M., Marques, M. P. M., Ferreira, I. M. P. L. V. O., Mota‐Filipe, H., & Diniz, C. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.012 · Cited by 159
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity
CHIEN, J. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27698 · Cited by 146
Baritaki, S., Huerta‐Yépez, S., Sakai, T., Spandidos, D. A., & Bonavida, B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0521 · Cited by 153
Eckschlager, T., Adam, V., Hrabeta, J., Figova, K., & Kizek, R. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309788922243 · Cited by 144
Holzer, A. K., Katano, K., Klomp, L. W. J., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0748 · Cited by 143
Tangeretin Alleviates Cisplatin-Induced Acute Hepatic Injury in Rats: Targeting MAPKs and Apoptosis
Omar, H. A., Mohamed, W. R., Arab, H. H., & Arafa, E.-S. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151649 · Cited by 142
“only 15–20% due to the development of resistance [1].”
BackgroundChoi, K. J., Piao, Y. J., Lim, M. J., Kim, J. H., Ha, J., Choe, W., & Kim, S. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1759 · Cited by 155
The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin
Rivel, T., Ramseyer, C., & Yesylevskyy, S. O. (2019) · Scientific Reports · doi:10.1038/s41598-019-41903-w · Cited by 142
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
Balch, C., Yan, P. S., Craft, T. R., Young, S. R. L., Skalnik, D. G., Huang, T. H. ‐., & Nephew, K. P. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0216 · Cited by 151
Liu, J., Zhang, H., Zhang, Y., Li, N., Wen, Y., Cao, F., Ai, H., & Xue, X. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0145 · Cited by 139
“The cytotoxicity of cisplatin was considered based on several factors, such as oxidative stress, energetic metabolism impairment, and DNA injury (Santos et al., 2007; Siddik, 2003).”
BackgroundPabla, N., Dong, G., Jiang, M., Huang, S., Kumar, M. V., Messing, R. O., & Dong, Z. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45586 · Cited by 155
Wang, Z., Xu, Z., & Zhu, G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608936 · Cited by 144
Mitochondrial Involvement in Cisplatin Resistance
Cocetta, V., Ragazzi, E., & Montopoli, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143384 · Cited by 150
“), proteins or mitochondrial structures, as well as with the mitochondrial DNA (mtDNA) [12,20].”
BackgroundStewart, J. J., White, J. T., Yan, X. S., Collins, S. J., Drescher, C. W., Urban, N. D., Hood, L., & Lin, B. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500140-mcp200 · Cited by 140
Groessl, M., Zava, O., & Dyson, P. J. (2011) · Metallomics · doi:10.1039/c0mt00101e · Cited by 161
Coluccia, D., Figueiredo, C. A., Wu, M. Y., Riemenschneider, A. N., Diaz, R., Luck, A., Smith, C., Das, S., Ackerley, C., O’Reilly, M., et al. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.01.021 · Cited by 139
Transition metal compounds as cancer radiosensitizers
Gill, M. R., & Vallis, K. A. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00641e · Cited by 138
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Havasi, A. D., Cainap, S. S., Havasi, A. T., & Cainap, C. I. (2023) · Medicina · doi:10.3390/medicina59030544 · Cited by 179
“As a result, platinum-resistant cell lines display a reduction in cisplatin concentration, varying from 20% to 70% [30].”
BackgroundMechanisms of Resistance to Conventional Therapies for Osteosarcoma
Marchandet, L., Lallier, M., Charrier, C., Baud’huin, M., Ory, B., & Lamoureux, F. (2021) · Cancers · doi:10.3390/cancers13040683 · Cited by 148
“That is why the most studied drug in the case of resistance due to increased DNA repair is CDP [96,126].”
BackgroundHexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents
Vajpayee, V., Yang, Y. J., Kang, S. C., Kim, H., Kim, I. S., Wang, M., Stang, P. J., & Chi, K. (2011) · Chemical Communications · doi:10.1039/c1cc10167f · Cited by 137
Chen, Y.-C., Lou, X., Zhang, Z., Ingram, P., & Yoon, E. (2015) · Scientific Reports · doi:10.1038/srep12175 · Cited by 136
Punchihewa, C., Inoue, A., Hishiki, A., Fujikawa, Y., Connelly, M., Evison, B., Shao, Y., Heath, R., Kuraoka, I., Rodrigues, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353201 · Cited by 135
Recent advances in drug delivery systems for enhancing drug penetration into tumors
He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831106 · Cited by 134
“Chemotherapy using small molecule drugs, such as doxorubicin (Cohen et al., 2012), camptothecin (Liu et al., 2008), paclitaxel (Von Hoff et al., 2011), or cisplatin (Siddik, 2003) are the most commonly-used anti-tumor treatments (Sherman-Baust et al., 2011).”
BackgroundAsymmetric triplex metallohelices with high and selective activity against cancer cells
Faulkner, A. D., Kaner, R. A., Abdallah, Q., Clarkson, G. J., Fox, D. J., Gurnani, P., Howson, S. E., Phillips, R. M., Roper, D. I., Simpson, D. H., et al. (2014) · Nature Chemistry · doi:10.1038/nchem.2024 · Cited by 145
Cisplatin binding to human serum albumin: a structural study
Ferraro, G., Massai, L., Luigi Messori, A., & Merlino, A. (2015) · Chemical Communications · doi:10.1039/c5cc01751c · Cited by 136
The plant‐specific CDKB1‐CYCB1 complex mediates homologous recombination repair in Arabidopsis
Weimer, A. K. K., Biedermann, S., Harashima, H., Roodbarkelari, F., Takahashi, N., Foreman, J., Guan, Y., Pochon, G., Heese, M., Damme, D. V., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593083 · Cited by 138
“…to DNA breaks also intraand interstrand DNA links that require repair by HR in contrast to damage caused by BLM and HU that can also be repaired by NHEJ (Kartalou & Essigmann, 2001; Belenkov et al, 2002; De Silva et al, 2002; Fuertes et al, 2002; Crul et al, 2003; Siddik, 2003; Pinato et al, 2014).”
MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation
Jin, L., Chun, J., Pan, C., Li, D., Lin, R., Alesi, G. N., Wang, X., Kang, H.-B., Song, L., Wang, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.012 · Cited by 132
“Cisplatin exerts anticancer effects mainly by interacting with DNA to form mostly intrastrand crosslink adducts, which activates proapoptotic signal transduction pathways (Siddik, 2003).”
BackgroundOncosis-inducing cyclometalated iridium( iii ) complexes
Guan, R., Chen, Y., Zeng, L., Rees, T. W., Jin, C., Huang, J., Chen, Z., Ji, L., & Chao, H. (2018) · Chemical Science · doi:10.1039/c8sc01142g · Cited by 132
Chtourou, Y., Aouey, B., Kebieche, M., & Fetoui, H. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.06.036 · Cited by 150
He, C., Liu, D., & Lin, W. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.017 · Cited by 129
The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance
Giacomini, I., Ragazzi, E., Pasut, G., & Montopoli, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030937 · Cited by 150
“Many studies showed that the consequence of such mechanisms of resistance is attenuated apoptosis [6,9,11].”
BackgroundGadhikar, M. A., Sciuto, M. R., Alves, M. V. O., Pickering, C. R., Osman, A. A., Neskey, D. M., Zhao, M., Fitzgerald, A. L., Myers, J. N., & Frederick, M. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0157 · Cited by 133
USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
Sonego, M., Pellarin, I., Costa, A., Vinciguerra, G. L. R., Coan, M., Kraut, A., D’Andrea, S., Dall’Acqua, A., Castillo-Tong, D. C., Califano, D., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav3235 · Cited by 126
Ling, Y., Xia, X., Liang, H., Wang, W., Zhang, H., Liu, L., Liu, W., Li, Z., Tan, C., & Mao, Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210988 · Cited by 134
Novel benzyl substituted titanocene anti-cancer drugs
Sweeney, N. J., Mendoza, Ó., Müller‐Bunz, H., Pampillón, C., Rehmann, F. K., Strohfeldt, K. A., & Tacke, M. (2005) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2005.06.039 · Cited by 129
Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity
Fu, Y., Habtemariam, A., Pizarro, A. M., van Rijt, S., Healey, D. J., Cooper, P. A., Shnyder, S. D., Clarkson, G. J., & Sadler, P. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100560f · Cited by 132
Polymeric drug delivery of platinum-based anticancer agents
Haxton, K. J., & Burt, H. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21611 · Cited by 137
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Wu, C., Wangpaichitr, M., Feun, L., Kuo, M. T., Robles, C., Lampidis, T., & Savaraj, N. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-25 · Cited by 125
Wu, X., Wu, Y., Ye, H., Yu, S., He, C., & Chen, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.011 · Cited by 127
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
Hill, D. P., Harper, A., Malcolm, J., McAndrews-Hill, M., Mockus, S. M., Patterson, S. E., Reynolds, T., Baker, E. J., Bult, C. J., Chesler, E. J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6278-9 · Cited by 138
“Response to cisplatin can be modulated by a number of different mechanisms: decreased cellular import or increased cellular efflux of cisplatin, detoxification of cisplatin, defective DNA repair or resistance to cell cycle arrest or cell death [25, 67, 68].”
BackgroundTowards a molecular understanding of human diseases using Dictyostelium discoideum
Williams, R. S. B., Boeckeler, K., Gräf, R., Müller‐Taubenberger, A., Li, Z., Isberg, R. R., Wessels, D. J., Soll, D. R., Alexander, H., & Alexander, S. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.003 · Cited by 125
Bauer, J. A., Trask, D. K., Kumar, B., Los, G., Castro, J., Shin-Jung Lee, J., Chen, J., Wang, S., Bradford, C. R., & Carey, T. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0081 · Cited by 124
Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells
BAO, L., JARAMILLO, M. C., ZHANG, Z., ZHENG, Y., YAO, M., ZHANG, D. D., & YI, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2671 · Cited by 123
“The five‑year survival rate for ovarian cancer patients is currently ~30% (2).”
Ren, J.-H., He, W.-S., Nong, L., Zhu, Q.-Y., Hu, K., Zhang, R.-G., Huang, L.-L., Zhu, F., & Wu, G. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0701 · Cited by 123
Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson, D. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111353 · Cited by 129
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Kim, B., Sun, S., Varner, J. A., Howell, S. B., Ruoslahti, E. I., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201902952 · Cited by 127
Lv, J., Yuan, W., Yin, J., Chen, Y., Zhou, G., Chen, W., Liang, X., Zhang, Y., Zhang, C., He, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02369-6 · Cited by 138
The histone chaperone Asf1 at the crossroads of chromatin and DNA checkpoint pathways
Mousson, F., Ochsenbein, F., & Mann, C. (2006) · Chromosoma · doi:10.1007/s00412-006-0087-z · Cited by 140
Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses
Kishi, S., Brooks, C. R., Taguchi, K., Ichimura, T., Mori, Y., Akinfolarin, A., Gupta, N., Galichon, P., Elias, B. C., Suzuki, T., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122313 · Cited by 117
“Cisplatin induces DNA damage by causing inter- and intra-strand crosslinks, leading to replication fork arrest and single-strand breaks in human kidney organoids (30, 31).”
BackgroundThe anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear
García‐Berrocal, J. R., Nevado, J., Ramírez‐Camacho, R., Fernández, R. S., González-García, J. Á., Sánchez‐Rodríguez, C., Cantos, B., España, P., Verdaguer, J. M., & Cabezas, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707405 · Cited by 139
Chekhun, V. F., Lukianova, N. Y., Kovalchuk, O., Tryndyak, V., & Pogribny, I. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0663 · Cited by 131
Lauritzen, G., Jensen, M. B. F., Boedtkjer, E., Dybboe, R., Aalkjær, C., Nylandsted, J., & Pedersen, S. F. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.06.005 · Cited by 129
Brotin, É., Meryet‐Figuière, M., Simonin, K., Duval, R. E., Villedieu, M., Leroy‐Dudal, J., Saison-Behmoaras, E., Gauduchon, P., Denoyelle, C., & Poulain, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24787 · Cited by 120
Kalayda, G. V., Wagner, C. H., Buß, I., Reedijk, J., & Jaehde, U. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-175 · Cited by 120
Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells
Lin, J., Lin, Y., Tsai, T., Chen, H., Chou, K., & Hwang, I.-S. T. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s126464 · Cited by 128
“28 Investigating resistant mechanisms in BC is essential for developing therapeutic strategies for improving cancer therapy.”
Role of Nucleotide Excision Repair in Cisplatin Resistance
Duan, M., Ulibarri, J., Liu, K. J., & Mao, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239248 · Cited by 142
“Cisplatin-induced DNA crosslinks can strongly inhibit replicative DNA polymerases and induce apoptosis [4], which explains why cisplatin selectively kills fast-proliferating cancer cells.”
BackgroundPhytochemicals: Current strategy to sensitize cancer cells to cisplatin
Sun, C., Zhang, Q.-Y., Zheng, G., & Feng, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.010 · Cited by 130
Conti, L., Macedi, E., Giorgi, C., Valtancoli, B., & Fusi, V. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214656 · Cited by 126
Liang, X.-J., Finkel, T., Shen, D.-W., Yin, J.-J., Aszalos, A., & Gottesman, M. M. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2130 · Cited by 117
Mellor, H. R., Ferguson, D. J. P., & Callaghan, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602710 · Cited by 116
Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity
Dolan, M. E., Newbold, K. G., Nagasubramanian, R., Wu, X., Ratain, M. J., Cook, E. H., & Badner, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0340 · Cited by 116
Liedert, B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl051 · Cited by 115
hMSH2 Recruits ATR to DNA Damage Sites for Activation during DNA Damage-induced Apoptosis
Pabla, N., Ma, Z., McIlhatton, M. A., Fishel, R., & Dong, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210989 · Cited by 107
Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
Puigvert, J. C., Sanjiv, K., & Helleday, T. (2016) · The FEBS Journal · doi:10.1111/febs.13574 · Cited by 113
The role of copper transporters in the development of resistance to Pt drugs
Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114
Chan, M. M., Soprano, K. J., Weinstein, K., & Fong, D. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20569 · Cited by 114
Palladium complexes: new candidates for anti-cancer drugs
Jahromi, E. Z., Divsalar, A., Saboury, A. A., Khaleghizadeh, S., Mansouri‐Torshizi, H., & Kostova, I. P. (2016) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-015-0804-8 · Cited by 118
Mitra, I., Mukherjee, S., B., V. P. R., Dasgupta, S., Bose, J. C., Mukherjee, S., Linert, W., & Moi, S. C. (2016) · RSC Advances · doi:10.1039/c6ra17788c · Cited by 129
Hsu, H.-Y., Lin, T.-Y., Hu, C.-H., Shu, D. T. F., & Lu, M.-K. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.006 · Cited by 116
Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy
Cheng, X., Feng, D., Lv, J., Cui, X., Wang, Y., Wang, Q., & Zhang, L. (2023) · Cancers · doi:10.3390/cancers15030666 · Cited by 126
“Cisplatin is highly electrophilic compound so it can potentially react with nucleophilic sites of both nuclear DNA both DNA-RNA-protein of mitochondria) [71].”
BackgroundCombination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“Cisplatin induces DNA damage and apoptosis, which may be attenuated by DNA repair systems [36].”
BackgroundWANG, F., Zhou, J., Xie, X., Hu, J., CHEN, L., Hu, Q., GUO, H., & Yu, C. (2015) · Neoplasma · doi:10.4149/neo_2015_051 · Cited by 112
Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin
Shiu, L., Chang, L.-C., Liang, C., Huang, Y., Sheu, H. M., & Kuo, K. (2007) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.05.009 · Cited by 128
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0205 · Cited by 110
Biological functions of the ING family tumor suppressors
Campos, E. I., Chin, M. Y., Kuo, W., & Li, G. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4199-4 · Cited by 133
Min, J., Mesika, A., Sivaguru, M., Van Veldhoven, P. P., Alexander, H., Futerman, A. H., & Alexander, S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0100 · Cited by 112
An Msh2 Conditional Knockout Mouse for Studying Intestinal Cancer and Testing Anticancer Agents
Kucherlapati, M. H., Lee, K., Nguyen, A. A., Clark, A. B., Hou, H., Rosulek, A., Li, H., Yang, K., Fan, K., Lipkin, M., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.009 · Cited by 111
Tom, L. N., Bywater, M. J., Gu, W., Saunders, N. A., Gabrielli, B. G., Leggatt, G. R., & McMillan, N. A. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014191 · Cited by 120
Barilli, A., Atzeri, C., Bassanetti, I., Ingoglia, F., Dall’Asta, V., Bussolati, O., Maffini, M., Mucchino, C., & Marchiò, L. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400592n · Cited by 124
Wang, H., Lin, C., Chiu, J., Chow, K., Kuo, K., Lin, C., & Wang, L. (2007) · International Journal of Cancer · doi:10.1002/ijc.22402 · Cited by 118
Shi, Y., Zhai, H., Wang, X., Han, Z., Liu, C., Lan, M., Du, J.-P., Guo, C., Zhang, Y., Wu, K., et al. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.009 · Cited by 111
Chen, S.-F., Nieh, S., Jao, S., Liu, C., Wu, C.-H., Chang, Y., Yang, C., & Lin, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049275 · Cited by 113
Sun, R. W., Lok, C., Fong, T. T., Li, C. K.-L., Yang, Z. F., Zou, T., Siu, F., & Che, C. (2013) · Chemical Science · doi:10.1039/c3sc21972k · Cited by 113
Conjugation of vitamin E analog α-TOS to Pt(iv) complexes for dual-targeting anticancer therapy
Suntharalingam, K., Song, Y., & Lippard, S. J. (2013) · Chemical Communications · doi:10.1039/c3cc48740g · Cited by 112
Glutathione in Ovarian Cancer: A Double-Edged Sword
Nunes, S. C., & Serpa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071882 · Cited by 119
Sun, X., Wang, S., Gai, J., Guan, J., Li, J., Li, Y., Zhao, J., Zhao, C., Fu, L., & Li, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00754 · Cited by 116
“Cisplatin, one of the most widely applied chemotherapeutic agents for multiple solid tumors including ovarian cancer, was initially described as a DNA intrastrand cross-linker that interacts with DNA to form DNA adducts, resulting in the activation of several signal transduction pathways including those involved in DN…”
BackgroundPaciello, F., Fetoni, A. R., Mezzogori, D., Rolesi, R., Pino, A. D., Paludetti, G., Grassi, C., & Troiani, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-57965-0 · Cited by 118
Deswal, Y., Asija, S., Kumar, D., Jindal, D. K., Chandan, G., Panwar, V., Saroya, S., & Kumar, N. (2021) · Research on Chemical Intermediates · doi:10.1007/s11164-021-04621-5 · Cited by 110
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.